Accelerating ADC Discovery through Strategically Integrated Chemistry, Biology, and DMPK

Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar demonstrates how integrated strategies help overcome these hurdles and support informed preclinical decisions.

Innovative chemistry enables efficient conjugation, optimized linkers, and payload selection, while addressing critical challenges such as linker bottlenecks, photosensitizer compatibility, and product homogeneity. A Photo-ADC case study illustrates how these strategies translate into precise targeting and potent cytotoxicity.

Multimodal biological assays — including cell-line cytotoxicity, high-content phenotyping, and molecular signaling markers such as Y-H2AX, RPA2, P53, PARP, and P21 — reveal ADC potency and mechanism-of-action, providing a physiologically relevant assessment of efficacy.

Complementing these efforts, specialized DMPK workflows for ADC discovery, including untargeted LC-HRMS profiling to characterize payload-related species, support understanding of ADC disposition and guide ADME and potential drug–drug interaction (DDI) study design, providing robust preclinical insights.

Join us to learn how integrated chemistry, biology, and DMPK strategies can streamline ADC discovery and support better early-stage decisions.